Nasdaq · Healthcare
Protagonist Therapeutics, Inc (PTGX)
As-reported financials and recent SEC filings for Protagonist Therapeutics, Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$46.0M
Net income
$-130.1M
Net margin
—
Diluted EPS
$-2.05
ROE
-21.2%
P/E (TTM)
—
Market cap
$7.84B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $46.0M | $434.4M | $60.0M | $26.6M | $27.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $-158.1M | $252.8M | $-93.7M | $-131.4M | $-125.8M |
| Net income | $-130.1M | $275.2M | $-79.0M | $-127.4M | $-125.6M |
| Diluted EPS | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-25
View on EDGAR →1442026-06-23
View on EDGAR →8-K2026-06-18
View on EDGAR →42026-06-11
View on EDGAR →1442026-06-10
View on EDGAR →42026-06-01
View on EDGAR →1442026-05-29
View on EDGAR →4/A2026-05-14
View on EDGAR →Go deeper on PTGX
Search Protagonist Therapeutics, Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.